Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Accelerate Diagnostics (AXDX)
:AXDX
RESEARCH TOOLSreports
Holding AXDX?
Track your performance easily
AXDX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.73 - $2.09
Previous CloseN/A
Volume11.64K
Average Volume (3M)78.63K
Market Cap
$28.05M
Enterprise Value$80.67M
Total Cash (Recent Filing)$77.76M
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.92
Next Earnings
Feb 25, 2025EPS Estimate
-0.5Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.72
Shares Outstanding25,043,821
10 Day Avg. Volume44,877
30 Day Avg. Volume78,625
Standard Deviation0.26
R-Squared0.01
Alpha-0.05
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)2.36
Price to Cash Flow (P/CF)-2.30
P/FCF Ratio0.00
Enterprise Value/Market Cap2.88
Enterprise Value/Revenue6.77
Enterprise Value/Gross Profit31.63
Enterprise Value/Ebitda-1.85
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Accelerate Diagnostics News
PremiumCompany Announcements
Accelerate Diagnostics Reports Key Advances Amid Financial Challenges
PremiumCompany Announcements
Accelerate Diagnostics Unveils Executive Incentive Plan Linked to FDA Goals
PremiumCompany Announcements
Accelerate Diagnostics’ Shareholder Decisions at Annual Meeting
Ownership Overview
39.60% Insiders
2.42% Mutual Funds
14.64% Other Institutional Investors
41.44% Public Companies and
Individual Investors
AXDX FAQ
What was Accelerate Diagnostics’s price range in the past 12 months?
Accelerate Diagnostics lowest stock price was $0.73 and its highest was $2.09 in the past 12 months.
What is Accelerate Diagnostics’s market cap?
Accelerate Diagnostics’s market cap is $28.05M.
When is Accelerate Diagnostics’s upcoming earnings report date?
Accelerate Diagnostics’s upcoming earnings report date is Feb 25, 2025 which is in 38 days.
How were Accelerate Diagnostics’s earnings last quarter?
Accelerate Diagnostics released its earnings results on Nov 07, 2024. The company reported -$0.544 earnings per share for the quarter, missing the consensus estimate of -$0.471 by -$0.073.
Is Accelerate Diagnostics overvalued?
According to Wall Street analysts Accelerate Diagnostics’s price is currently Overvalued.
Does Accelerate Diagnostics pay dividends?
Accelerate Diagnostics does not currently pay dividends.
What is Accelerate Diagnostics’s EPS estimate?
Accelerate Diagnostics’s EPS estimate is -0.5.
How many shares outstanding does Accelerate Diagnostics have?
Accelerate Diagnostics has 25,043,821 shares outstanding.
What happened to Accelerate Diagnostics’s price movement after its last earnings report?
Accelerate Diagnostics reported an EPS of -$0.544 in its last earnings report, missing expectations of -$0.471. Following the earnings report the stock price went down -7.107%.
Which hedge fund is a major shareholder of Accelerate Diagnostics?
Currently, no hedge funds are holding shares in AXDX
---
Accelerate Diagnostics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bearish
AXDX Sentiment 70%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 42.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $314.0K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-50.34%
12-Months-Change
Fundamentals
Return on Equity
110.26%
Trailing 12-Months
Asset Growth
-17.82%
Trailing 12-Months
Company Description
Accelerate Diagnostics
Accelerate Diagnostics, Inc. is an in vitro diagnostics company, which engages in the provision of solutions that improve patient outcomes and lower healthcare costs through the rapid diagnosis of serious infections. It also focuses on developing and commercializing innovative instrumentation for the rapid identification and antibiotic susceptibility testing of infectious pathogens. Its products include Accelerate Pheno and Accelerate PhenoTest. The company was founded on May 26, 1982 and is headquartered in Tucson, AZ.
---
AXDX Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mixed view with several positive achievements such as progress in clinical trials, FDA clearance for new systems, and improved gross margins. However, these were balanced by challenges like decreased net sales and ongoing net losses. The strategic focus on innovation and market leadership is promising, yet financial metrics indicate areas needing attention.Read More>---
Technical Analysis
T2 Biosystems
―
VolitionRX
―
Senseonics Holdings
―
Illumina
―
Thermo Fisher
―
QuidelOrtho
―
---